AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37533657
Drug: High-intensity laser
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity laser therapy (HILT) + stretching exercise
Trial: 37533657
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) + stretching exercise
Trial: 37533867
Drug: rBCG-N-hRSV vaccine
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rBCG-N-hRSV vaccine
Trial: 37534543
Drug: Fostamatinib (a
RxNorm normalized name: fostamatinib (as disodium hexahydrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib (a SYK inhibitor)
Trial: 37534999
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy using nanovesicles
Trial: 37534996
Drug: gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine plus nab-paclitaxel in combination with indoximod
Trial: 37535240
Drug: Avalglucosidase alfa
RxNorm normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Avalglucosidase alfa (AVAL) at a dosage of 20 mg/kg
Trial: 37535240
Drug: Avalglucosidase alfa
RxNorm normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Avalglucosidase alfa (AVAL) at a dosage of 40 mg/kg
Trial: 37535357
Drug: Telephone-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based cognitive behavioral therapy (tele-CBT) consisting of 6 weekly 1-hour sessions and a booster session 1 month later.
Trial: 37535377
Drug: Camrelizumab plus
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab plus chemotherapy (200 mg camrelizumab, nab-paclitaxel 130 mg/m2, cisplatin 75 mg/m2 or carboplatin AUC 5 or nedaplatin 100 mg/m2)
Trial: 37535382
Drug: Aflibercept, 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept, 8 mg (70 μL)
Trial: 37535382
Drug: Aflibercept, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept, 2 mg (50 μL)
Trial: 37535388
Drug: Standard second-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard second-line chemotherapy
Trial: 37535416
Drug: Machine Learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine Learning Clinical Decision Support (ML-CDS) tool
Trial: 37535416
Drug: ML-CDS intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ML-CDS intervention
Trial: 37535416
Drug: ML-CDS tool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML-CDS tool
Trial: 37535419
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of melatonin
Trial: 37535419
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of melatonin
Trial: 37535521
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ABC-I)
Trial: 37535555
Drug: Mindfulness-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based therapy (MBT) ROC-T
Trial: 37535555
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) ROC-T
Trial: 37535618
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of remimazolam tosylate and propofol (R+P group)
Trial: 37535775
Drug: All interventions
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All interventions (Ozone, Steroid, Pulsed Radiofrequency)
Trial: 37535953
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (no HBV treatment)
Trial: 37535953
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (single HBV treatment)
Trial: 37535953
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (dual HBV treatment)
Trial: 37536936
Drug: TLPLDC+G (n=56)
RxNorm normalized name: N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLPLDC+G (n=56)
Trial: 37536941
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg every 2 weeks for a total of 17 doses) and ipilimumab (1 mg/kg every 6 weeks for a total of 6 doses) starting 2 weeks prior to radiotherapy
Trial: 39639088
Drug: Afatinib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (40 mg daily)
Trial: 37537548
Drug: Two distinct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two distinct approaches to involving parents in adolescent obesity treatment
Trial: 37537580
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin (LMWH) alone
Trial: 37537580
Drug: LMWH and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH and aspirin
Trial: 37538173
Drug: Brensocatib (QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brensocatib (QD dosing)
Trial: 37538539
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 125 μg subcutaneous pegylated IFNβ-1a
Trial: 37538951
Drug: Colistin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin monotherapy (5 mg/kg once followed by 1.67 mg/kg every 8 hours)
Trial: 37538951
Drug: Colistin in
RxNorm normalized name: colistin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin in combination with meropenem (1000 mg every 8 hours)
Trial: 37540036
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) added to furosemide, eGFR-adjusted doses
Trial: 37540566
Drug: One or
RxNorm normalized name: Geone Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One or two infusions of third-generation CD19-directed CAR-Ts (2 × 10^8/m2)
Trial: 37540593
Drug: Thyroid hormones
RxNorm normalized name: Thyroid hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormones (TSH, T3, T4) and sex hormones (PRL, total testosterone) measured preoperatively and at 24 h postoperatively
Trial: 37540921
Drug: CCRT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCRT plus TIL infusion (n = 78)
Trial: 37541263
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (randomised pathway)
Trial: 37541263
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment (randomised pathway)
Trial: 37541263
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (patient choice pathway)
Trial: 37541263
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment (patient choice pathway)
Trial: 37541273
Drug: Erdafitinib (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdafitinib (8 mg/day, with potential up-titration to 9 mg/day)
Trial: 37541600
Drug: Abstinence-Contingent Wage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abstinence-Contingent Wage Supplement
Trial: 37541683
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of ropivacaine 0.2% 4-8 mL/hour
Trial: 37541683
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of ropivacaine 0.5%, 20 mL
Trial: 37541705
Drug: Dispersible and
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible and immediate-release FDC abacavir (60 mg or 600 mg), dolutegravir (5 mg or 50 mg), and lamivudine (30 mg or 300 mg) tablets taken once per day.
Trial: 37541921
Drug: 3.36 g
RxNorm normalized name: IODINE 33.36 g in 1 L TOPICAL SOLUTION [NU-OPT 330]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.36 g eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily for 30 months
Trial: 37541951
Drug: Ketamine (subanaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (subanaesthetic doses, blood concentration of 0.2-0.3 μg ml)
Trial: 37542222
Drug: GMB/GMB group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMB/GMB group (galcanezumab 120 mg)
Trial: 37542222
Drug: PBO/GMB group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBO/GMB group (placebo followed by galcanezumab 240 mg loading dose and then two 120 mg doses)
Trial: 37542234
Drug: Exercise snacking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise snacking intervention (twice daily for 28 days, consisting of five muscle-strengthening exercises)
Trial: 37542331
Drug: Breakfast Task
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Breakfast Task training (5 sessions, 45 minutes each, delivered online, twice a week)
Trial: 37542470
Drug: Lanreotide (LAN)
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanreotide (LAN) treatment initiation
Trial: 37542470
Drug: Lanreotide (LAN)
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanreotide (LAN) treatment
Trial: 37542674
Drug: Mini-oral sulfate
RxNorm normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-oral sulfate tablet (mini-OST)
Trial: 37542674
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral sulfate tablet (OST)
Trial: 37543437
Drug: Conventional oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oxygen treatment with a Venturi mask
Trial: 37543575
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus paravertebral block (ropivacaine 0.5% loading, 0.2% infusion)
Trial: 37543590
Drug: Tablet without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet without the PREVEDEL software (Control group)
Trial: 37543602
Drug: MRI scan,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI scan, neuropsychological tests, ophthalmic examination
Trial: 37544143
Drug: Triple antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antithrombotic treatment consisting of subcutaneous enoxaparin, VKA, and discontinued aspirin
Trial: 37544326
Drug: cAd3-EBO S
RxNorm normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cAd3-EBO S vaccine at 1 × 10^11 viral particles
Trial: 37544326
Drug: cAd3-EBO S
RxNorm normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cAd3-EBO S vaccine at 1 × 10^10 viral particles
Trial: 37544492
Drug: Urine chemistry-guided
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urine chemistry-guided diuretic strategy
Trial: 37545290
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CYFRA 21-1 and CA 125 biomarkers
Trial: 37545298
Drug: Intermittent low-carbohydrate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent low-carbohydrate diet (ILCD) - carbohydrate intake ≤ 50 g/d on seven nonconsecutive days
Trial: 37545392
Drug: CAP-100 (anti-CCR7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP-100 (anti-CCR7 antibody)
Trial: 37545406
Drug: Lacosamide (LCM)
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lacosamide (LCM) up to 12 mg/kg/day or 600 mg/day
Trial: 37545580
Drug: Delayed oral
RxNorm normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed oral feeding (DOF)
Trial: 38466872
Drug: VR neuroscience-based
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR neuroscience-based therapy (VRNT)
Trial: 37547448
Drug: Posttreatment residual
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posttreatment residual tumors in the breast and lymph nodes after neoadjuvant chemotherapy
Trial: 37547664
Drug: Gonadotoxic childhood
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotoxic childhood therapy
Trial: 37548010
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis for acute stroke in the prehospital setting
Trial: 37548555
Drug: UGN-102 once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGN-102 once weekly for 6 weeks
Trial: 37548555
Drug: Transurethral resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral resection of bladder tumor monotherapy
Trial: 37548831
Drug: Chemotherapy (n=77)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (n=77)
Trial: 37548850
Drug: Intravenous bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous bevacizumab (IA BEV)
Trial: 37549351
Drug: Acromegaly treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acromegaly treatment
Trial: 37549598
Drug: LCPUFA-ω3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCPUFA-ω3 supplementation (225 mg DHA, 45 mg EPA, administered at 0.100 g/kg of body weight/day for 3 months)
Trial: 37549598
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (500 mg sunflower oil)
Trial: 37549675
Drug: PFCs as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFCs as adjunct in cancer therapies
Trial: 37549680
Drug: BNT162b2 (third
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 (third dose)
Trial: 37549724
Drug: Bedside family
RxNorm normalized name: Bedside-Care
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bedside family planning counseling and offer of contraception (oral contraceptive pills, etonogestrel implant, or medroxyprogesterone injection)
Trial: 37549933
Drug: Dexamethasone 0.5 mg/5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.5 mg/5 mL in Mucolox™
Trial: 37549933
Drug: Dexamethasone 0.5 mg/5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.5 mg/5 mL solution (standard arm)
Trial: 37550019
Drug: Single-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oral secnidazole 2 g
Trial: 37550157
Drug: Elevated serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated serum alkaline phosphatase (ALP) quartile Q4 (ALP >83.00 U/L)
Trial: 37550429
Drug: Blinatumomab (immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab (immunotherapy drug)
Trial: 37550730
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care followed by delayed treatment with TranS-C (UC-DT)
Trial: 37551324
Drug: Active surveillance
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active surveillance (weekly)
Trial: 37551324
Drug: Immunoglobulin G
RxNorm normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin G positivity
Trial: 37551412
Drug: 150 min/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 min/wk of moderate-intensity aerobic, resistance, or combination exercise
Trial: 37551532
Drug: Drug-Eluting Balloon
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Eluting Balloon (DEB) angioplasty (SEQUENT PLEASE)
Trial: 37551532
Drug: Drug-Eluting Stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Eluting Stent (DES) (Promus Premier and Promus Elite)
Trial: 37551550
Drug: Labisia pumila
RxNorm normalized name: Ulmus pumila pollen
DrugBank: Ulmus pumila pollen (DB10362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labisia pumila standardized extract (SKF7®) 750 mg
Trial: 37551841
Drug: Fibrin-based haemostatic
RxNorm normalized name: Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGplPTH1-34
DrugBank: KUR-113 (DB18413)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin-based haemostatic agents (FBHAs)
Trial: 37552083
Drug: Therapies reported
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapies reported
Trial: 37552303
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg/d (n=150)
Trial: 37552330
Drug: Vitamin K4
RxNorm normalized name: Vitamin K4
DrugBank: Acetomenaphthone (DB19387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K4 (1 mg) for 24 weeks
Trial: 37552407
Drug: Telmisartan (10-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (10-80 mg daily)
Trial: 37552407
Drug: Enalapril (5-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5-40 mg daily)
Trial: 37553338
Drug: inactivated SARS-CoV-2
RxNorm normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactivated SARS-CoV-2 vaccine
Trial: 37553488
Drug: MRI-guided focused
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-guided focused ultrasound (MRgFUS) treatment
Trial: 37554078
Drug: Insulin-controlled euglycemia
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-controlled euglycemia (control)
Trial: 37554078
Drug: Total insulin
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total insulin withdrawal for 14 hours
Trial: 37554125
Drug: Sintilimab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (200 mg, day 1) plus bevacizumab (7.5 mg/kg, day 1), oxaliplatin (135 mg/m2, day 1), and capecitabine as first-line therapy
Trial: 37554510
Drug: Intravenous reinduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous reinduction of Ustekinumab (UST) followed by subcutaneous q8w or q4w
Trial: 37555284
Drug: Entinostat 2
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entinostat 2 mg orally weekly in combination with standard dose carboplatin, etoposide, and atezolizumab
Trial: 37555345
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) plus optimal medical and device therapy (OMT)
Trial: 37555345
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical and device therapy (OMT) alone
Trial: 37555595
Drug: Low-dose ato-oxy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ato-oxy (0.5 mg/kg atomoxetine and 5 mg oxybutynin)
Trial: 37555595
Drug: High-dose ato-oxy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ato-oxy (1.2 mg/kg atomoxetine and 5 mg oxybutynin)
Trial: 37556515
Drug: Tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tildrakizumab 100 mg subcutaneously at week 0, week 4, and every 12 weeks thereafter
Trial: 37556515
Drug: Tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tildrakizumab 100 mg subcutaneously
Trial: 37556775
Drug: Palbociclib +
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib + Endocrine Therapy (ET)
Trial: 37556856
Drug: Plyometric high-intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plyometric high-intensity interval training (PLYO), 8 weeks, twice weekly
Trial: 37556856
Drug: Cycle-oriented high-intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle-oriented high-intensity interval training (CYC), 8 weeks, twice weekly